Compounds > 1-methyl-3-isobutylxanthine
Page last updated: 2024-10-29

1-methyl-3-isobutylxanthine and (pPNET) Peripheral Primitive Neuroectodermal Tumors

1-methyl-3-isobutylxanthine has been researched along with (pPNET) Peripheral Primitive Neuroectodermal Tumors in 2 studies

1-Methyl-3-isobutylxanthine: A potent cyclic nucleotide phosphodiesterase inhibitor; due to this action, the compound increases cyclic AMP and cyclic GMP in tissue and thereby activates CYCLIC NUCLEOTIDE-REGULATED PROTEIN KINASES
3-isobutyl-1-methylxanthine : An oxopurine that is xanthine which is substituted at positions 1 and 3 by methyl and isobutyl groups, respectively.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Mania-Farnell, BL2
Merrill, BJ2
Yamamura, HI1
Davis, TP2
Konings, PN1

Other Studies

2 other studies available for 1-methyl-3-isobutylxanthine and (pPNET) Peripheral Primitive Neuroectodermal Tumors

ArticleYear
Second messenger activators regulate CCK mRNA in the human neuroepithelioma cell line SK-N-MCIXC.
    Annals of the New York Academy of Sciences, 1994, Mar-23, Volume: 713

    Topics: 1-Methyl-3-isobutylxanthine; 8-Bromo Cyclic Adenosine Monophosphate; Cell Line; Cholecystokinin; Exo

1994
Regulation of CCK mRNA in the human neuroepithelioma cell line SK-N-MCIXC in response to second messenger activators.
    FEBS letters, 1993, Nov-29, Volume: 335, Issue:1

    Topics: 1-Methyl-3-isobutylxanthine; 8-Bromo Cyclic Adenosine Monophosphate; Cell Line; Cholecystokinin; Cyc

1993